2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylic acid hydrazide | 80843-46-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylic acid hydrazide
• 英文别名: 3-oxo-6-pyridin-4-yl-2,3-dihydro-pyridazine-4-carboxylic acid hydrazide；6-oxo-3-pyridin-4-yl-1H-pyridazine-5-carbohydrazide
• CAS: 80843-46-5
• 化学式: C₁₀H₉N₅O₂
• 分子量: 231.214
• InChiKey: PMUZKPNRBITVHX-UHFFFAOYSA-N

物化性质

• 熔点：
  212-213 °C
• 密度：
  1.57±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylic acid hydrazide 在 盐酸 、 sodium nitrite 作用下， 以 P2 O5 、 水 为溶剂， 生成 2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylic acid azide monohydrochloride
  参考文献：
  名称：

  4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as

  摘要：

  2-R-4-R'-6-PY-3(2H)-吡啶并咪唑酮（I）或其盐，可作为中间体和一些作为心脏强心剂，通过将二（较低烷基）羟基[2-氧代-2-PY-乙基]丙二酸酯（II）与公式RNHNH.sub.2.nH.sub.x An（III）的肼盐反应制备，以产生较低烷基2,3-二氢-2-R-3-氧代-6-PY-4-吡啶并咪唑羧酸酯（Ia，其中R'为较低碳烷氧基），并将Ia与肼水合物或无水肼反应，以产生2,3-二氢-2-R-3-氧代-6-PY-4-吡啶并咪唑羧酸肼（Ib，其中R'为氨基羰基），其中PY为4-或3-吡啶基或带有一个或两个较低烷基取代基的4-或3-吡啶基，R为氢、较低烷基或较低羟基烷基，R'为羰基、羧基、氨基羰基或较低碳烷氧基，n为1或2，x为1、2或3，An为强无机酸或有机磺酸的阴离子。还显示了：从PY--COCH.sub.3（IV）制备II，将Ia转化为Ib（其中R'为羧基），以及将2-R-4-R"-6-PY-3(2H)-吡啶并咪唑酮（I，其中R为较低烷基或较低羟基烷基，R"为羰基、氨基羰基或较低碳烷氧基）用作心脏强心剂。还显示了其他中间体。

  公开号：

  US04304776A1
• 作为产物：
  描述：

  diethyl hydroxy<2-oxo-2-(4-pyridinyl)ethyl>propanedioate 在 盐酸肼 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 23.5h， 生成 2,3-dihydro-3-oxo-6-(4-pyridinyl)-4-pyridazinecarboxylic acid hydrazide
  参考文献：
  名称：

  Synthesis of Aza Analogs of Amrinone

  摘要：

  The aldol condensation product (4) of 4-acetylpyridine (2) and diethyl mesoxalate (3) was converted to pyridazinecarboxylic acid hydrazide (6). Curtius reaction of 6 gave aminopyridazinone (7). The condensation of (4-pyridinyl)glyoxal (17) with aminomalonamide (9) yielded pyrazinecarboxamide (18) which was transformed to aminopyrazinone (19) by the Hofmann reaction. Curtius reaction of 1,2,4-triazinone-5-carboxylic acid (21b) gave aminotriazinone (22). Demethylation of methoxypyrimidine (29) prepared from methyl 2-methoxyformylacetate (25) and isonicotinamidine (26) gave pyrimidinol (30).

  DOI：

  10.3987/com-90-5562

文献信息

• Novel pyridazinone derivatives as inhibitors of CDK2
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1598348A1

  公开（公告）日：2005-11-23

  The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2)

  本发明涉及符合通式（I）的化合物，其中下文给出了取代基X、R1和R2的定义，以及它们的生理上可接受的盐，以及制备这些化合物的方法以及它们作为药物的用途。 这些化合物是激酶抑制剂，特别是激酶CDK2（细胞周期依赖性激酶2）的抑制剂。
• [EN] PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DERIVES DE PYRIDAZINONE, PROCEDES DE PRODUCTION DE CES DERIVES ET LEUR UTILISATION COMME PHARMACEUTIQUES
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2005111018A1

  公开（公告）日：2005-11-24

  The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. Formula (I) These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK­15 30 (glycogen synthase kinase-3ß).

  本发明涉及通式（I）所示的化合物，其中下文给出了取代基X、R1和R2的定义，以及它们的生理上可接受的盐，生产这些化合物的方法以及它们作为药物的用途。通式（I）这些化合物是激酶抑制剂，特别是激酶GSK-15 30（糖原合成酶激酶-3ß）的抑制剂。
• 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics
  申请人：Sterling Drug Inc.

  公开号：US04305943A1

  公开（公告）日：1981-12-15

  4-Amino-2-R-6-PY-3(2H)-pyridazinones (I) or salts thereof, which are useful as cardiotonics, where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents are prepared by: (a) reaction of 2-R-6-PY-3(2H)-pyridazinone (II) with hydrazine; (b) conversion from 2,3-dihydro-2-R-3-oxo-6-PY-4-pyridazinecarboxamide (III); or, (c) conversion form 2,3-dihydro-2-R-3-oxo-6-PY-4-pyridazinecarboxylic acid hydrazide (IV). Also shown are: the use of I or salts as cardiotonic agents; and, the preparation of intermediates.

  4-氨基-2-R-6-PY-3(2H)-吡啶并嗪酮(I)或其盐，可用作心力衰竭药物，其中R为氢、低烷基或低羟基烷基，PY为4-或3-吡啶基或带有一个或两个低烷基取代基的4-或3-吡啶基，通过以下方法制备：(a) 2-R-6-PY-3(2H)-吡啶并嗪酮(II)与肼的反应；(b) 从2,3-二氢-2-R-3-氧代-6-PY-4-吡啶并嗪甲酰胺(III)转化而来；或(c) 从2,3-二氢-2-R-3-氧代-6-PY-4-吡啶并嗪羧酸肼酰肼(IV)转化而来。还显示了：将I或其盐用作心力衰竭药物；以及中间体的制备。
• Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from
  申请人：Sterling Drug Inc.

  公开号：US04346221A1

  公开（公告）日：1982-08-24

  4-Amino-2-R-6-PY-3(2H)-pyridazinones (I) or salts thereof, which are useful as cardiotonics, where R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents are prepared by: (a) reaction of 2-R-6-PY-3(2H)-pyridazinone (II) with hydrazine; (b) conversion from 2,3-dihydro-2-R-3-oxo-6-PY-4-pyridazinecarboxamide (III); or, (c) conversion form 2,3-dihydro-2-R-3-oxo-6-PY-4-pyridazinecarboxylic acid hydrazide (IV). Also shown are: the use of I or salts as cardiotonic agents; and, the preparation of intermediates.

  4-氨基-2-R-6-PY-3（2H）-吡啶嗪酮（I）或其盐，可用作心脏强心剂，其中R为氢，低烷基或低羟基烷基，PY为4-或3-吡啶基或带有一个或两个低烷基取代基的4-或3-吡啶基，通过以下方法制备：（a）2-R-6-PY-3（2H）-吡啶嗪酮（II）与肼反应；（b）由2,3-二氢-2-R-3-氧代-6-PY-4-吡啶嗪羧酰胺（III）转化而来；或（c）由2,3-二氢-2-R-3-氧代-6-PY-4-吡啶嗪羧酸肼（IV）转化而来。还显示了：将I或其盐用作心脏强心剂的用途；以及中间体的制备。
• PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS
  申请人：Hoelder Swen

  公开号：US20070088041A1

  公开（公告）日：2007-04-19

  The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R 1 and R 2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3β(glycogen synthase kinase-3β).

  本发明涉及符合通式（I）的化合物，其中X，R1和R2的定义如下文所述，以及它们的生理学上可接受的盐，制备这些化合物的方法以及它们作为药物的用途。这些化合物是激酶抑制剂，特别是激酶GSK-3β（糖原合成酶激酶-3β）的抑制剂。